JP6771698B1 - ウルソデオキシコール酸を含有する老視の治療または予防剤 - Google Patents

ウルソデオキシコール酸を含有する老視の治療または予防剤 Download PDF

Info

Publication number
JP6771698B1
JP6771698B1 JP2020520162A JP2020520162A JP6771698B1 JP 6771698 B1 JP6771698 B1 JP 6771698B1 JP 2020520162 A JP2020520162 A JP 2020520162A JP 2020520162 A JP2020520162 A JP 2020520162A JP 6771698 B1 JP6771698 B1 JP 6771698B1
Authority
JP
Japan
Prior art keywords
acid
ursodeoxycholic
ester
ursodeoxycholic acid
therapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2020520162A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020129964A1 (ja
Inventor
雅智 加藤
雅智 加藤
知子 小田
知子 小田
一貴 木戸
一貴 木戸
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Application granted granted Critical
Publication of JP6771698B1 publication Critical patent/JP6771698B1/ja
Publication of JPWO2020129964A1 publication Critical patent/JPWO2020129964A1/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
JP2020520162A 2018-12-18 2019-12-17 ウルソデオキシコール酸を含有する老視の治療または予防剤 Expired - Fee Related JP6771698B1 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2018236717 2018-12-18
JP2018236717 2018-12-18
PCT/JP2019/049352 WO2020129964A1 (ja) 2018-12-18 2019-12-17 ウルソデオキシコール酸を含有する老視の治療または予防剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020163766A Division JP2021006548A (ja) 2018-12-18 2020-09-29 ウルソデオキシコール酸を含有する老視の治療または予防剤

Publications (2)

Publication Number Publication Date
JP6771698B1 true JP6771698B1 (ja) 2020-10-21
JPWO2020129964A1 JPWO2020129964A1 (ja) 2021-02-15

Family

ID=71100366

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020520162A Expired - Fee Related JP6771698B1 (ja) 2018-12-18 2019-12-17 ウルソデオキシコール酸を含有する老視の治療または予防剤
JP2020163766A Pending JP2021006548A (ja) 2018-12-18 2020-09-29 ウルソデオキシコール酸を含有する老視の治療または予防剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020163766A Pending JP2021006548A (ja) 2018-12-18 2020-09-29 ウルソデオキシコール酸を含有する老視の治療または予防剤

Country Status (16)

Country Link
US (3) US20220072012A1 (enExample)
EP (1) EP3900728A4 (enExample)
JP (2) JP6771698B1 (enExample)
KR (1) KR20210105916A (enExample)
CN (1) CN113164499A (enExample)
AU (1) AU2019407391A1 (enExample)
BR (1) BR112021011653A2 (enExample)
CA (1) CA3123370A1 (enExample)
EA (1) EA202191684A1 (enExample)
IL (1) IL284004A (enExample)
MX (1) MX2021007161A (enExample)
MY (1) MY203280A (enExample)
PH (1) PH12021551412A1 (enExample)
SG (1) SG11202106216SA (enExample)
TW (1) TW202038966A (enExample)
WO (1) WO2020129964A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021006548A (ja) * 2018-12-18 2021-01-21 参天製薬株式会社 ウルソデオキシコール酸を含有する老視の治療または予防剤

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3210908A1 (en) 2021-02-15 2022-08-18 Santen Pharmaceutical Co., Ltd. Water-based pharmaceutical composition containing ursodeoxycholic acid or salt thereof
US20220349486A1 (en) * 2021-04-29 2022-11-03 Baker Hughes Oilfield Operations Llc Modulating pilot valve adapter
TW202412751A (zh) * 2022-08-09 2024-04-01 日商參天製藥股份有限公司 含有udca或其鹽之水性醫藥組合物
CN116211804B (zh) * 2023-05-09 2025-09-05 北京汇诚益健医药科技有限责任公司 熊去氧胆酸脂质组合物及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106074568A (zh) * 2015-09-02 2016-11-09 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
WO2018147685A1 (ko) * 2017-02-09 2018-08-16 주식회사 유스바이오팜 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2442647B1 (en) 2009-06-15 2016-03-16 Encore Health LLC Dithiol compounds, derivatives, and uses therefor
CN102178784B (zh) * 2011-04-20 2013-06-12 威海康博尔生物药业有限公司 一种用于缓解视疲劳的药物组合物
US9724357B2 (en) * 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
CN104083381A (zh) * 2014-07-29 2014-10-08 上海中医药大学 熊去氧胆酸的医药用途
WO2016029197A1 (en) * 2014-08-22 2016-02-25 Kang Zhang Compositions and methods to treat and/or prevent vision disorders of the lens of the eye
KR102252450B1 (ko) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
JP6771698B1 (ja) * 2018-12-18 2020-10-21 参天製薬株式会社 ウルソデオキシコール酸を含有する老視の治療または予防剤

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106074568A (zh) * 2015-09-02 2016-11-09 盛世泰科生物医药技术(苏州)有限公司 一种用于预防和治疗白内障的眼用制剂及其制备方法
WO2018147685A1 (ko) * 2017-02-09 2018-08-16 주식회사 유스바이오팜 우르소데옥시콜산을 함유하는 시각장애 예방 또는 치료용 조성물
WO2018164113A1 (ja) * 2017-03-06 2018-09-13 学校法人 慶應義塾 マウス近視誘導モデル及び近視予防・抑制のための小胞体ストレス抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AMANY, ABDEL-GHAFFAR ET AL.: "Ursodeoxycholic acid suppresses the formation of fructose/streptozotocin-induced diabetic cataract i", FUNDAMENTAL & CLINICAL PHARMACOLOGY, vol. 32, no. 6, JPN6020009657, 31 December 2018 (2018-12-31), pages 627 - 640, ISSN: 0004273968 *
SONG, SHUHUA ET AL.: "Cholesterol-derived bile acids enhance the chaperone activity of α-crystallins.", CELL STRESS & CHAPERONES, vol. 16, no. 5, JPN6020009656, 2011, pages 475 - 480, ISSN: 0004273967 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021006548A (ja) * 2018-12-18 2021-01-21 参天製薬株式会社 ウルソデオキシコール酸を含有する老視の治療または予防剤

Also Published As

Publication number Publication date
BR112021011653A2 (pt) 2021-09-08
SG11202106216SA (en) 2021-07-29
EP3900728A1 (en) 2021-10-27
EA202191684A1 (ru) 2021-09-01
JP2021006548A (ja) 2021-01-21
US20220096497A1 (en) 2022-03-31
KR20210105916A (ko) 2021-08-27
AU2019407391A1 (en) 2021-07-01
WO2020129964A1 (ja) 2020-06-25
US20230040386A1 (en) 2023-02-09
US20220072012A1 (en) 2022-03-10
JPWO2020129964A1 (ja) 2021-02-15
CN113164499A (zh) 2021-07-23
IL284004A (en) 2021-08-31
EP3900728A4 (en) 2022-08-17
CA3123370A1 (en) 2020-06-25
TW202038966A (zh) 2020-11-01
PH12021551412A1 (en) 2022-05-02
MX2021007161A (es) 2021-10-13
US11419880B2 (en) 2022-08-23
MY203280A (en) 2024-06-21

Similar Documents

Publication Publication Date Title
JP6771698B1 (ja) ウルソデオキシコール酸を含有する老視の治療または予防剤
JP7474706B2 (ja) ４－フェニル酪酸を含有する老視の治療または予防剤
RU2602738C2 (ru) Комбинация фолиевой кислоты и рамиприла: цитопротекторные, нейропротекторные и ретинопротекторные офтальмологические композиции
CN119546278A (zh) 两性离子在眼用局部乳膏组合物和制剂中的新应用
JP2022166224A (ja) 水性点眼液
JP2018024677A (ja) ラキニモドを使用する眼炎症性疾患の治療
CN114173788A (zh) 泪液分泌促进用眼科组合物
US11717513B2 (en) Mirabegron for the treatment of retinal diseases
JP2022152866A (ja) コール酸またはコール酸誘導体を含有する老視の治療または予防剤
JP6509244B2 (ja) 水晶体硬化抑制剤
KR102902220B1 (ko) 4-페닐부티르산을 함유하는 노시의 치료 또는 예방제
WO2020213693A1 (ja) リポ酸プロドラッグ
HK40056566A (en) Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤
CN110769855A (zh) 用于治疗视网膜病变的组合物和方法
HK40054770A (en) Ursodeoxycholic acid-containing agent for treating or preventing presbyopia
RU2836815C1 (ru) Офтальмологические композиции для местного применения на ксантановой основе с сокращенным режимом дозирования
JP7197112B2 (ja) 水泡性角膜症治療用医薬組成物

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200408

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20200408

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20200521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200814

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200901

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200929

R150 Certificate of patent or registration of utility model

Ref document number: 6771698

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees